A5057053396- Testicular diseases and treatments
- Ovarian cancer diagnosis and treatment
- Sarcoma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Brain Metastases and Treatment
- Multiple Myeloma Research and Treatments
- Urticaria and Related Conditions
- Advanced Radiotherapy Techniques
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Drug-Induced Adverse Reactions
- Gestational Trophoblastic Disease Studies
- Mast cells and histamine
- Ocular Oncology and Treatments
- Boron Compounds in Chemistry
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Drug-Induced Ocular Toxicity
- Urologic and reproductive health conditions
- Sperm and Testicular Function
- Hepatocellular Carcinoma Treatment and Prognosis
- Sexual Differentiation and Disorders
- Cancer Cells and Metastasis
University Medical Center Hamburg-Eppendorf
2012-2018
Universität Hamburg
2012-2018
Martini-Klinik
2012
Universitätsklinikum Aachen
2011
Hôpital Bichat-Claude-Bernard
2000
Hôpital Avicenne
1995
Forty percent of non-small cell lung cancer (NSCLC) patients develop brain metastases, resulting in a dismal prognosis. However, an oligo-metastatic disease setting seem to have better outcomes. Here, we investigate the possibility using circulating tumor cells (CTCs) as biomarkers differentiate for risk assessment. Using CellSearch® system, few CTCs were detected among NSCLC with metastases (n = 52, 12.5% ≥ two and 8.9% five CTC/7.5 mL blood) especially 34, 5.9%, 2.9%). Still, thresholds...
4597 Background: Bone metastases (mets) are rare events in GCT patients (pts) and data on characteristics, risk factors, treatment outcome these pts largely missing. Methods: A subgroup of 104 ptswith bone metsfrom the IPFSG database was analyzed. All experienced unequivocal relapse/progression after > 3 cycles cisplatin-based chemotherapy received conventional-dose (CDCT) or high-dose salvage (HDCT). Results: / 1594 presented with mets (6,5%) at first relapse. Histology pure seminoma...
4559 Background: About 20-30% of patients (pts) with advanced germ-cell cancer (GCC) relapse after cisplatin-based chemotherapy. This database evaluates first salvage treatment and the prognostic categories at according to International Prognostic Factors Study Group (= IPFSG; JCO 2010). Methods: A total 144 pts (78% nonseminoma) relapsed or refractory GCC undergoing 1 st either conventional (CD-CX) high-dose chemotherapy autologous stem cell support (HD-CX) from 16 German centers were...